Nyxoah Appoints John Landry as Chief Financial Officer
November 04 2024 - 4:45PM
Nyxoah Appoints John Landry as Chief
Financial Officer
Current CFO, Loïc Moreau, to Transition into Role
of President International
Mont-Saint-Guibert, Belgium – November
4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA
(Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the
“Company”), a medical technology company that develops breakthrough
treatment alternatives for Obstructive Sleep Apnea (OSA) through
neuromodulation, today announced the appointment of John Landry as
Chief Financial Officer (CFO), effective November 4, 2024. This
strategic appointment, in combination with the recent move to the
United States of CEO Olivier Taelman, strengthens the Company’s
focus on the U.S. market.
Mr. Landry brings over two decades of financial
leadership experience in the healthcare and medtech sectors, with a
proven track record of driving growth and operational efficiency in
public and private companies. Most recently, he served as CFO at
Vapotherm Inc., where he played an instrumental role in executing
financial strategies that supported significant revenue growth and
market share expansion in the U.S. market.
“We are delighted to welcome John to Nyxoah. His
deep financial expertise and extensive experience in the U.S.
healthcare landscape in combination with his strong investor
relations experience will be invaluable as we accelerate our growth
in this critical market,” said Olivier Taelman, CEO of Nyxoah.
“John’s leadership will help us further optimize our financial
strategies and drive operational efficiencies as we prepare Genio
for commercialization in the US.”
Additionally, Nyxoah announces that Loïc Moreau,
currently CFO, will transition into the newly created role of
President International. In this capacity, Mr. Moreau will
spearhead Nyxoah’s global expansion efforts, focusing on
strengthening the Company’s presence in key international
markets.
This announcement reflects Nyxoah’s commitment
to building a strong, diversified leadership team to support its
ambitious growth objectives.
About NyxoahNyxoah is
reinventing sleep for the billion people that suffer from
obstructive sleep apnea (OSA). We are a medical technology company
that develops breakthrough treatment alternatives for OSA through
neuromodulation. Our first innovation is Genio®, a battery-free
hypoglossal neuromodulation device that is inserted through a
single incision under the chin and controlled by a wearable.
Through our commitment to innovation and clinical evidence, we have
shown best-in-class outcomes for reducing OSA burden.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Nyxoah completed two successful IPOs: on Euronext Brussels in
September 2020 and NASDAQ in July 2021. Following the positive
outcomes of the BETTER SLEEP study, Nyxoah received CE mark
approval for the expansion of its therapeutic indications to
Complete Concentric Collapse (CCC) patients, currently
contraindicated in competitors’ therapy. Additionally, the Company
announced positive outcomes from the DREAM IDE pivotal study for
FDA and U.S. commercialization approval.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this
press release are forward-looking, reflecting Nyxoah's current
expectations and beliefs regarding the Genio® system; planned and
ongoing clinical studies of the Genio® system; the potential
advantages of the Genio® system; Nyxoah’s goals with respect to the
development, regulatory pathway and potential use of the Genio®
system; the utility of clinical data in potentially obtaining FDA
approval of the Genio® system; and potential receipt of FDA
approval and entrance into the U.S. market. By their nature,
forward-looking statements involve a number of risks,
uncertainties, assumptions and other factors that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties, assumptions and factors could adversely affect the
outcome and financial effects of the plans and events described
herein. Additionally, these risks and uncertainties include, but
are not limited to, the risks and uncertainties set forth in the
“Risk Factors” section of Nyxoah’s Annual Report on Form 20-F for
the year ended December 31, 2023, filed with the Securities and
Exchange Commission (“SEC”) on March 20, 2024, and subsequent
reports that Nyxoah files with the SEC. A multitude of factors
including, but not limited to, changes in demand, competition and
technology, can cause actual events, performance or results to
differ significantly from any anticipated development. Forward
looking statements contained in this press release regarding past
trends or activities are not guarantees of future performance and
should not be taken as a representation that such trends or
activities will continue in the future. In addition, even if actual
results or developments are consistent with the forward-looking
statements contained in this press release, those results or
developments may not be indicative of results or developments in
future periods. No representations and warranties are made as to
the accuracy or fairness of such forward-looking statements. As a
result, Nyxoah expressly disclaims any obligation or undertaking to
release any updates or revisions to any forward-looking statements
in this press release as a result of any change in expectations or
any change in events, conditions, assumptions or circumstances on
which these forward-looking statements are based, except if
specifically required to do so by law or regulation. Neither Nyxoah
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Contacts:
NyxoahLoïc
MoreauIR@nyxoah.com
For MediaIn United StatesFINN
Partners – Glenn Silverglenn.silver@finnpartners.com
In Belgium/FranceBackstage Communication –
Gunther De Backergunther@backstagecom.be
In International/GermanyMC Services – Anne
Henneckenyxoah@mc-services.eu
- ENGLISH_Nyxoah Appoints John Landry as Chief Financial
Officer
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Nov 2023 to Nov 2024
